EuroBioForum2014_speaker_Metspalu
-
Upload
eurobioforum -
Category
Health & Medicine
-
view
198 -
download
0
description
Transcript of EuroBioForum2014_speaker_Metspalu
Andres Metspalu Director of the Estonian Genome Center
of the University of Tartu, Estonia
National perspective Estonia
Estonian Biobank and Personalised Medicine
Andres Metspalu, M.D., Ph.D Estonian Genome Center
University of Tartu
EuroBioForum, Tallinn September 22, 2014
Estonian Biobank • Estonian Genome Center,
University of Tartu • A prospective, longitudinal,
population-based database with health records and biological materials
• 52,000 participants - 5% of the adult population of Estonia
• Individuals are recruited by GPs, physicians in the hospitals and medical personnel in the EGCUT recruitment offices
• Estonian Human Genes Research Act (HGRA)
§ 3. Chief processor of Gene Bank
• (1) The chief processor of the Gene Bank is the University of Tartu, whose objectives as the chief processor are to:
• 1) promote the development of genetic research;
• 2) collect information on the health of the Estonian population and genetic information concerning the Estonian population;
• 3) use the results of genetic research to improve public health.
§ 11. Other rights of gene donors
• Gene donors have the right not to know their genetic data
• Gene donors have the right to access personally their data stored in the Gene Bank
• Gene donors do not have the right to access their genealogies
• Gene donors shall not be charged for accessing their data stored in the Gene Bank
• Gene donors have the right to genetic counseling upon accessing their data stored in the Gene Bank
• Gene donors have the right to submit additional information on themselves to the chief processor
• Gene donors have the right to prohibit the supplementation, renewal and verification of descriptions of their state of health stored in the Gene bank.
• A registered individual has the right to receive, upon request, information concerning his or her health as determined based on a sample. When providing information determined based on the sample, the person must be provided with an opportunity to receive an account of the significance of the information. A fee may be charged for clarifying the significance of the information that, at maximum, corresponds to the expenses incurred by providing the clarification.
688/2012 Biobank Act
1. Sept. 2013 Finland
EGCUT cohort vs Estonian population
1820
25
30
35
40
45
50
55
60
65
70
75
80
85+
EGCUT males
EGCUT femalesEstonian population
Age
No of gene donors by age group
Estonian population by age group (01.01.2008)
700 500 300 100 100 300 500 700
15000 10000 5000 0 5000 10000 15000
Public opinion and awareness of the EGCUT 2001-2013
-0.05
-0.03
-0.01
0.01
0.03
0.05
0.07
-0.05 -0.03 -0.01 0.01 0.03 0.05
P2
1 (4
.68
%)
PC1 (8.65%)
Austria Bulgaria Czech Republic
Estonia Finland (Helsinki) Finland (Kuusamo)
France Northern Germany Southern Germany
Hungary Northern Italy Southern Italy
Latvia Lithuania Poland
Russia Spain Sweden
Switzerland
-0.1
-0.08
-0.06
-0.04
-0.02
0
0.02
0.04
0.06
0.08
0.1
-0.12 -0.07 -0.02 0.03
PC
2 2
3.8
%
PC1 36.6%
Europe
CHB
JPT
YRI
CEU
Per Med Definition in EU documents
• Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention
This is the EU H2020 definition of the Per Med.
What do we need for implementing personalized medicine?
- Deep understanding variations and its meaning in the population
- E-Health system, which covers the whole country and all providers
- Technology to analyze genomes - Automated decision support software in order to help
primary care providers and others - Database for genomic variations and related phenotypes
(disease risk alleles and variants causing the adverse drug reaction)
- Educated medical workers, executives, med students and teachers
- Public acceptance
Medical genetics (Mendelian Diseases?) - newborn screening - microarray analysis (InfiniumDx CytoSNP-12 BeadChip) - exome sequencing All covered by Estonian Health Care Insurance Fund
What is going on today?
Medical genomics (Complex Common Diseases? - biobank - eHealth - microarray analysis - full genome sequencing - seases
Marta Garcia Martinez de Lecea and Michael Rossbach. Translational genomics in personalized medicine – scientific challenges en route to clinical practice. The HUGO Journal 2012, 6:2; http://www.thehugojournal.com/content/6/1/2
Carbamazepine Carbamazepine
e.g. Carbamazepine
CLIPMERGE: How it works When you are with a patient that has enrolled in the CLIPMERGE study
and you prescribe a medication, this is what happens:
CRAE (CLIPMERGE Risk Assessment
Engine)
1. Physician prescribes a medication and signs order in Epic
2. A medication message is generated by Epic and sent to CLIPMERGE Risk Assessment
Engine (CRAE)
3. CRAE contains the patient’s genotype data, some clinical data and rules associating
particular genotypes and particular medications or clinical features with an alert (BPA)
4. If a rule is fulfilled, CRAE generates an alert Message and sends it back to Epic
5. The alert is displayed within Epic as a BPA and SmartSet
6. If the BPA is acknowledged or the original order is changed, Epic sends another
message to CRAE to let it know
Prof. E. Böttinger
What is Clinical Decision Support Engine (CDSE)?
• CDSE provides clinicians with knowledge presented at appropriate times
• It encompasses a variety of tools such as computerized alerts, clinical guidelines, and order sets
• CDSE has the potential provide the necessary level of personalized guidance to providers at the point of care that will be necessary in the era of genomic medicine
PHARMACIS AND FAMILY DOCTORS 2009
X-Roads, ID-card, State IS Service Register
HEA
LTH
CA
RE
BO
AR
D
- H
ealt
h c
are
pro
vid
ers
- Hea
lth
pro
fess
ion
als
- D
isp
ensi
ng
chem
ists
ST
ATE
AG
ENC
Y O
F M
EDIC
INES
- C
od
ing
Cen
tre
- H
and
lers
of
med
icin
es
PO
PU
LATI
ON
REG
ISTE
R
PH
AR
MA
CIS
2
01
0 ja
nu
ary
BU
SIN
ESS
REG
ISTE
R
HO
SPIT
ALS
20
09
FAM
ILY
DO
CTO
RS
2009
SCH
OO
L N
UR
SES
20
10
sep
tem
ber
EMER
GEN
CY
MED
ICA
L SE
RV
ICE
2013
NATIONAL HEALTH INFORMATION SYSTEM 2008 december
PRESCRIPTION CENTRE 2010 january
PATIENT PORTAL 2009
XROADS GATEWAY SERVICE 2009
IT Architectural “Big picture”
Documents total – 10.8 mio
1.1 mio persons medical data (growth 20% during 2012)
National Patient Portal
Do we have enough information to start?
Known risk factors for many common complex diseases
• BMI
• Alcohol consumtion
• Smoking
• Already existing diseases
• Family history
• Biomarkers
What does genetics add?
• Add valuable information to traditional risk factors (1P)
• Genetic risk can be determined at an early age (1P)
• Markers remain the same during the lifetime (1P)
• Can motivate more to change the lifesryle (1P)
4 P Medicine !
Prevented deaths of CHD in Finland
By treating 2144 persons who have >20% risk when the genetic information is known 135 deaths would be prevented in 10 years!
Tikkanen, E. 2013. Genetic risk profiles for coronary heart disease
Polygenic risk score
Polygenic risk scores
• Genome-wide association studies (GWAS) have discovered a large number of genetic variants that are associated with common complex diseases.
• The effect of each individal marker (SNP) is in most cases not strong enough to justify their use in clinical practice
• Combining several markers across the genome leads to polygenic risk scores that already explain a large proportion of heritability of the trait and are a promising tool to aid personalized disease prediction
Economic burden of diabetes (GER) 2000-2007
• Prevalence of treated diabetes rose continuously from 6.5 to 8.9% (+36.8%)
• Direct costs per patient with diabetes rose from € 5 197 to € 5 726 (+10.2%)
• Total direct cost burden of diabetes in Germany grew from € 27.8 billion to € 42.0 billion (+51.1%)
• per-capita costs were € 2 400 in 2000 and € 2 605 in 2007 (+8.5%)
Exp Clin Endocrinol Diabetes 2011; 119(6): 377-385
Survey of primary care physicians
• Survey sent to 130 PCPs collaborating with the EGCUT, 65 responded
– 96.3% - either strongly agree or agree that a training program in genetics and genomics is necessary
– 75% - reported having patients show interest in their genomic health data
– 96.4% - believe that predictive genetic testing will improve health care
– 73.3% - believe that predictive genetic testing will be used in their practice in the next 5 years
– 35.8% - believe that individualized medicine will be used in their practice in the next 5 years
Estonian Reform Party and Social Democratic Party
coalition = current government
POLICY PAPER:
• Social security, labour market, healthcare
• 25. We will establish a course towards personalised medicine based on modern gene technology.
Proposal
Challenges and issues
• Awareness executives, doctors and patients • New technologies and data empower patient
with more possibilities to manage own health • Ethical issues
– Right to know and right not to know – Treatable and non-treatable conditions – Big data
• Not enough knowledge about associations between DNA variants and diseases
• Large work-load to keep database of known risk markers updated
Are we ready for the personalized medicine?
• E-health, EMR and other e-based infrastructures are in place
• Genome analysis technology can do the task
• Scientific and medical expertiese is here
• Genomic variations are excisting and they have an effect on human health and behavior
• People are interested in personalized, genome based health realted information
Conclusions
• Estonia has great potential to plan and implement personalized medicine solutions for the whole country, starting with the pilot project for 50 000 gene donors
– Genetic research with 5% of population genetic and continuously updated phenotype information
– Nation wide Health Information Exchange platform
– 10 years of experience of national level e-services (PKI, X-Road, ID-card, security framework)
– High level public trust and acceptance
Thank you!
www.biobank.ee